JP2024518178A - 眼疾患の治療のための増殖因子の組成物 - Google Patents

眼疾患の治療のための増殖因子の組成物 Download PDF

Info

Publication number
JP2024518178A
JP2024518178A JP2023570358A JP2023570358A JP2024518178A JP 2024518178 A JP2024518178 A JP 2024518178A JP 2023570358 A JP2023570358 A JP 2023570358A JP 2023570358 A JP2023570358 A JP 2023570358A JP 2024518178 A JP2024518178 A JP 2024518178A
Authority
JP
Japan
Prior art keywords
amino acids
seq
polypeptide
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023570358A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518178A5 (cg-RX-API-DMAC10.html
Inventor
ブリラ，ピョートル
シー オー，スーザン
クラーク アットウェル，エイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Claris Biotherapeutics Inc
Original Assignee
Claris Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Claris Biotherapeutics Inc filed Critical Claris Biotherapeutics Inc
Publication of JP2024518178A publication Critical patent/JP2024518178A/ja
Publication of JP2024518178A5 publication Critical patent/JP2024518178A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2023570358A 2021-05-14 2022-05-13 眼疾患の治療のための増殖因子の組成物 Pending JP2024518178A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188816P 2021-05-14 2021-05-14
US63/188,816 2021-05-14
PCT/US2022/072302 WO2022241465A1 (en) 2021-05-14 2022-05-13 Compositions of growth factor for the treatment of eye disease

Publications (2)

Publication Number Publication Date
JP2024518178A true JP2024518178A (ja) 2024-04-25
JP2024518178A5 JP2024518178A5 (cg-RX-API-DMAC10.html) 2025-05-19

Family

ID=81756753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023570358A Pending JP2024518178A (ja) 2021-05-14 2022-05-13 眼疾患の治療のための増殖因子の組成物

Country Status (12)

Country Link
US (1) US20230022990A1 (cg-RX-API-DMAC10.html)
EP (2) EP4337243A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024518178A (cg-RX-API-DMAC10.html)
KR (1) KR20240035394A (cg-RX-API-DMAC10.html)
CN (1) CN117677394A (cg-RX-API-DMAC10.html)
AU (1) AU2022272740A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023022474A2 (cg-RX-API-DMAC10.html)
CA (1) CA3218000A1 (cg-RX-API-DMAC10.html)
IL (1) IL308496A (cg-RX-API-DMAC10.html)
MX (1) MX2023012782A (cg-RX-API-DMAC10.html)
TW (1) TW202310868A (cg-RX-API-DMAC10.html)
WO (1) WO2022241465A1 (cg-RX-API-DMAC10.html)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010651A1 (en) * 1989-03-10 1990-09-20 Snow Brand Milk Products Co., Ltd. Glycoprotein of human origin, physiologically active factor comprising the same, and pharmaceutical preparation containing the same as active ingredient
WO1998040096A1 (en) * 1997-03-11 1998-09-17 Snow Brand Milk Products Co., Ltd. Preventives and/or remedies for multiple organ failure
WO2000072873A1 (fr) * 1999-05-31 2000-12-07 Mitsubishi Chemical Corporation Preparations lyophilisees de hgf
WO2015166885A1 (ja) * 2014-04-28 2015-11-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｈｇｆ凍結乾燥製剤
WO2016039163A1 (ja) * 2014-09-10 2016-03-17 クリングルファーマ株式会社 神経疾患の治療に適したｈｇｆ製剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5510329A (en) * 1988-04-26 1996-04-23 Ramot University For Applied Research And Industrial Development Ltd. Preparations for the treatment of eyes
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
JP2000344680A (ja) * 1999-05-31 2000-12-12 Mitsubishi Chemicals Corp Ｈｇｆ含有医薬組成物
WO2004026244A2 (en) * 2002-09-18 2004-04-01 Emiliano Ghinelli Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin
JP5093783B2 (ja) * 2006-04-20 2012-12-12 クリングルファーマ株式会社 Ｈｇｆ前駆体蛋白質改変体及びその活性型蛋白質
WO2008102452A1 (ja) 2007-02-22 2008-08-28 Kringle Pharma Inc. Ｈｇｆ製剤
US8895508B2 (en) * 2009-07-24 2014-11-25 Yasuhiki Tabata Methods for corneal endothelial proliferation using bFGF sustained-release gelatin hydrogel particles
JP6929273B2 (ja) * 2015-09-11 2021-09-01 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
US11479591B2 (en) * 2017-05-05 2022-10-25 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN116710568A (zh) * 2020-06-26 2023-09-05 特里福伊尔治疗公司 重组修饰成纤维细胞生长因子及其治疗用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010651A1 (en) * 1989-03-10 1990-09-20 Snow Brand Milk Products Co., Ltd. Glycoprotein of human origin, physiologically active factor comprising the same, and pharmaceutical preparation containing the same as active ingredient
WO1998040096A1 (en) * 1997-03-11 1998-09-17 Snow Brand Milk Products Co., Ltd. Preventives and/or remedies for multiple organ failure
WO2000072873A1 (fr) * 1999-05-31 2000-12-07 Mitsubishi Chemical Corporation Preparations lyophilisees de hgf
WO2015166885A1 (ja) * 2014-04-28 2015-11-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｈｇｆ凍結乾燥製剤
WO2016039163A1 (ja) * 2014-09-10 2016-03-17 クリングルファーマ株式会社 神経疾患の治療に適したｈｇｆ製剤

Also Published As

Publication number Publication date
IL308496A (en) 2024-01-01
CN117677394A (zh) 2024-03-08
US20230022990A1 (en) 2023-01-26
KR20240035394A (ko) 2024-03-15
AU2022272740A9 (en) 2023-11-09
BR112023022474A2 (pt) 2024-01-09
WO2022241465A1 (en) 2022-11-17
TW202310868A (zh) 2023-03-16
CA3218000A1 (en) 2022-11-17
EP4574211A2 (en) 2025-06-25
MX2023012782A (es) 2024-03-25
EP4574211A3 (en) 2025-09-10
EP4337243A1 (en) 2024-03-20
AU2022272740A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
Klenkler et al. Growth factors in the tear film: role in tissue maintenance, wound healing, and ocular pathology
US20120315256A1 (en) Use of transforming growth factor - beta 1 (tgf-b1) inhibitor peptides for the treatment of corneal fibrosis and/or haze
US6653284B2 (en) Keratinocyte growth factor-2 formulations
US20060287234A1 (en) Wound healing
CA2375829A1 (en) Keratinocyte growth factor-2 formulations
CN111148755A (zh) 重组经修饰成纤维细胞生长因子及其治疗用途
EP4031117B1 (en) Ngf mutant for use in treatment or prevention of ophthalmic disorders
KR20220047979A (ko) 안구 건조증에 대한 tsg6 폴리펩티드 단편
CN1638789A (zh) 用胸腺素β4(Tβ4)、类似物、异构体及其它衍生物治疗眼睛和周围组织失调的方法
US6869927B1 (en) Keratinocyte growth factor-2 formulations
US20110020449A1 (en) Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivatives
US20230022990A1 (en) Compositions of growth factor for the treatment of eye disease
US20090170780A1 (en) Protection of the retina against laser injury by nap and related peptides
WO2023092324A1 (zh) 多特异性配体结合分子及其应用
HK40128523A (en) Compositions of growth factor for the treatment of eye disease
US20240000891A1 (en) Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy
CN101232898A (zh) 血管内皮生长因子用于伤口愈合的用途
CN107428805A (zh) 短合成肽及其治疗和/或预防干眼症的用途
CA3147828C (en) Agent for use in treatment or prevention of ophthalmic disorders
HK40116769A (en) Multispecific ligand binding molecule and application thereof
HK1118017A (en) THE USE OF THYMOSIN β4, ANALOGUES, ISOFORMS AND OTHER DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING DISORDERS OF EYE AND THE SURROUNDING TISSUE

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260630